Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
New drugs for the treatment of human African trypanosomiasis: research anddevelopment
Autore:
Keiser, J; Stich, A; Burri, C;
Indirizzi:
Swiss Trop Inst, CH-4002 Basel, Switzerland Swiss Trop Inst Basel Switzerland CH-4002 st, CH-4002 Basel, Switzerland Univ Heidelberg, Inst Hyg, Abt Parasitol, D-69120 Heidelberg, Germany UnivHeidelberg Heidelberg Germany D-69120 , D-69120 Heidelberg, Germany
Titolo Testata:
TRENDS IN PARASITOLOGY
fascicolo: 1, volume: 17, anno: 2001,
pagine: 42 - 49
SICI:
1471-4922(200101)17:1<42:NDFTTO>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
S-ADENOSYLMETHIONINE DECARBOXYLASE; BRUCEI-RHODESIENSE INFECTIONS; BLOOD-STREAM FORMS; IN-VITRO; TRYPANOCIDAL ACTIVITY; ANTITRYPANOSOMAL ACTIVITY; SLEEPING SICKNESS; SERUM KINETICS; B-GAMBIENSE; INHIBITORS;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
75
Recensione:
Indirizzi per estratti:
Indirizzo: Burri, C Swiss Trop Inst, CH-4002 Basel, Switzerland Swiss Trop Inst Basel Switzerland CH-4002 02 Basel, Switzerland
Citazione:
J. Keiser et al., "New drugs for the treatment of human African trypanosomiasis: research anddevelopment", TRENDS PARA, 17(1), 2001, pp. 42-49

Abstract

Chemotherapy of human African trypanosomiasis is problematic because of the high frequency of severe adverse events, the long duration and high cost of treatment, and an increasing number of treatment-refractory cases. New cost-efficient, easy-to-use drugs are urgently needed. Whereas basic research on potential drug targets is anchored in academia, the complex, highly regulated and very expensive process of preclinical and clinical drug development is almost exclusively in the hands of pharmaceutical companies. Jennifer Keiser. August Stich and Christian Burri here review, from the angle of industrial drug research and development, the past ten years of research activities at different stages of the development of trypanocidal drugs, and assess future prospects. The absence of compounds in clinical development Phases I-III indicates no new drugs will become available in the next few years.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/03/20 alle ore 12:14:31